We are getting closer to Sublingual Immunotherapy (SLIT) in North America. Merck Sharpe and Dohme has now published a positive set of results for its phase III clinical trials of a SLIT treatment for grass allergy.

Grass allergy is a common seasonal allergy that results in a host of symptoms, including runny nose and itchy eyes. The investigational allergy immunotherapy tablet showed a positive effect in reducing such symptoms.

This is good news for patients. Sublingual Immunotherapy, unlike allergy shots, is a treatment that requires no needles and can be done at home. Reduced pain and increased convenience would likely make any SLIT treatment approach much preferred by patients with grass allergy.

Source: Zenopa